Top
Peritoneal Tumor - Healing Genes
738
post-template-default,single,single-post,postid-738,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Peritoneal Tumor

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer


Phase 1

DESCRIPTION:
Doctors at the Masonic Cancer Center of the University of Minnesota seek female patients with intraperitoneal primary tumors or recurrent ovarian or fallopian tube cancer that meets clinical criteria for its recurrence. These patients may be eligible for an investigatory treatment of donated (allogeneic) natural killer (NK) immune cells that target and may help to control tumors, along with in cell messengers (interleukin-2, or IL-2) to promote the immune system to fight the tumors. The trial seeks to determine best doses of NK cells.

Treatment will involve a cycle of chemotherapy, then the infusion of donor-matched NK cells and IL-2. Follow up continues for at least 1 year.


PATIENT MUST:

  • Be female, 18 years to 75 years old
  • Have a diagnosis of one of the eligible types of tumors
  • Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to FATE-NK100 cell infusion

THE STUDY INVOLVES:

  1. Screening to confirm acceptance to the study.
  2. Participants assigned to a dose level of NK cells based on when study is joined.
  3. Participants receive chemotherapy (Cyclophosphamide and Fludarabine), then receive NK cells intravenously.
  4. Interleukin-2 is given with the NK cells, three times a week for a total of 6 doses. The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion as an inpatient. The remaining doses will be given in an outpatient setting.
  5. Follow up will continue for at least 1 year after discharge.

LOCATIONS & CONTACTS:

The study will take place at the Masonic Cancer Center, University of Minnesota. Map.

Contact: Kimberly Brunsvold  |  612-626-2315  |  [email protected]

 

 

SPONSORS

Masonic Cancer Center, University of Minnesota

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03213964

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader